Erschienen in:
United European Gastroenterology Journal, 8 (2020) 5, Seite 528-535
Sprache:
Englisch
DOI:
10.1177/2050640620910339
ISSN:
2050-6406;
2050-6414
Entstehung:
Anmerkungen:
Beschreibung:
Albumin is currently employed as a plasma expander to prevent and treat specific complications of cirrhosis with ascites, such as the prevention of paracentesis‐induced circulatory dysfunction and renal dysfunction induced by spontaneous bacterial peritonitis, as well as the diagnosis and treatment of acute kidney injury and hepatorenal syndrome. Recently, evidence has shown that long‐term albumin administration in patients with decompensated cirrhosis reduces mortality and incidence of complications, eases the management of ascites, is cost effective, and has a good safety profile.